John M McCall

This inventor holds 46 USPTO granted patents and 5 published patent applications, primarily in CNS Treatments. Top assignees: The Upjohn Co., Pharmacia & Upjohn Company, Upjohn. Active years: 1977-2003.

USPTO Granted Patents = 46 (Patent Applications = 5)

% Patents Active = 97.8

Average Co-Inventor Count = 1.6

ph-index = 11

Forward Citations = 352(Granted Patents)

Company Filing History:

Pharmacia & Upjohn Company

4. 3 out of 834,307

Other

patents

Years Active: 1977-2003

Loading Chart...

Areas of Expertise:

Nervous Disorders

CNS Compounds

Piperazine

Steroids

Analgesics

Psychosis Treatment

Animal Feed

Benzothiepins

Amines

Angiogenesis

Tetrahydrobenzopyran

Isochromans

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6586427 - Treatments for nervous disorders (2003-07-01),

2. 6391876 - Reboxetine for treatment obsessive compulsive disorders and panic disorder (2002-05-21),

3. 6352986 - Treatments for nervous disorders (2002-03-05),

4. 5506354 - Imidazolylpiperazinyl steroids (1996-04-09),

5. 5382661 - Pyrazinylpiperazinyl steroids (1995-01-17),

6. 5380841 - Pyridinylpiperazinyl steroids (1995-01-10),

7. 5380840 - Triazinylpiperazinyl steroids (1995-01-10),

8. 5380839 - Phenylpiperazinyl steroids (1995-01-10),

9. 5322943 - Piperazine compounds which are substituted (1994-06-21),

10. 5268477 - Triazinylpiperazinyl amine intermediates (1993-12-07),

11. 5175281 - Pharmaceutically active pyrimidinylpiperazinylsterioids (1992-12-29),

12. 5120843 - Pharmaceutically active amines (1992-06-09),

13. 5099019 - Amines useful in producing pharmaceutically active CNS compounds (1992-03-24),

14. 4948533 - 11a-hydroxy steroid diester (1990-08-14),

15. 4771042 - Inhibition of angiogenesis involving the coadministration of steroids (1988-09-13),

Title: Unveiling the Innovative Mind of John M McCall

Introduction:

John M McCall, a brilliant inventor hailing from Kalamazoo, MI (US), has left an indelible mark in the field of medical advancements with a staggering 46 patents to his name.

Latest Patents:

McCall's latest patents showcase his dedication to advancing treatments for nervous disorders. One notable application describes innovative treatments for a range of conditions including addictive disorders, psychoactive substance use disorders, intoxication disorders, alcohol and tobacco addiction, and Attention Deficit Hyperactivity Disorder (ADHD) utilizing Reboxetine and its derivatives. Another groundbreaking invention focuses on the use of Reboxetine in Obsessive Compulsive Disorders and Panic Disorders.

Career Highlights:

With a rich history of innovation, McCall has contributed significantly to the field through his work at esteemed companies such as The Upjohn Company, where his inventive spirit thrived.

Collaborations:

During his tenure, McCall collaborated with esteemed professionals, including the likes of Frederick J VanDoornik and John R Palmer, amplifying the impact of his groundbreaking inventions.

Conclusion:

John M McCall's relentless pursuit of excellence in the realm of medical treatments for nervous disorders stands as a testament to his innovative prowess and unwavering commitment to improving healthcare outcomes. His legacy serves as an inspiration for future inventors and aspiring innovators alike.